A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
A Phase II Study of Combination Treatment with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma
Sponsor: Takara Bio Inc.
A PHASE2 clinical study on Melanoma Stage III and Melanoma Stage IV, this trial is completed. The trial is conducted by Takara Bio Inc. and has accumulated 13 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2019 — Apr 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Mar 2018 [monthly]
Recruiting PHASE2
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takara Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Chūō, Japan , Chūōku, Japan , Fukuoka, Japan , Kumamoto, Japan , Kurume, Japan , Nagakute, Japan , Nagoya, Japan , Niigata, Japan , Osaka, Japan , Sapporo, Japan and 2 more locations